Drug intelligence / Profile preview

Qipo Shengmai

Development stage: Unknown
Lead developer: China Academy of Chinese Medical Sciences
Administration: Oral

Overview

Qipo Shengmai is a Traditional Chinese Medicine (TCM) granule formulation developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is primarily indicated for the treatment of paroxysmal atrial fibrillation and atrial flutter, specifically in patients diagnosed with Qi and Yin deficiency syndrome. The formulation is a modification of the classic Shengmai San, typically incorporating Astragalus (Huangqi) and Amber (Hupo) to enhance its effects on nourishing Qi, enriching Yin, and stabilizing the heart rhythm. It is currently being evaluated in clinical trials for its efficacy and safety in managing cardiac arrhythmias.

Brand names: Qi Po Sheng Mai Granules
Other names: Qipo Shengmai granules芪珀生脉颗粒

Targets

NAMPT

Beyond the preview

Go deeper on Qipo Shengmai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qipo Shengmai.

Explore the full profile